Preclinical studies have shown that treatment with IMiDs enhances co-stimulation and proliferation of T cells by inducing pro-inflammatory cytokine (e.g. IFN-γ, TNF-α and IL-2), decreasing anti-inflammatory cytokines (e.g. IL-6 and IL-10) and potentiating DC-antigen presentation in MM and CLL (12, 192, 238, 239). This evidence concerns the gene IL6 and Miyoshi myopathy.